Epigenetic Regulation of HIV-1 Sense and Antisense Transcription in Response to Latency-Reversing Agents

被引:7
|
作者
Li, Rui [1 ]
Caico, Isabella [1 ]
Xu, Ziyan [1 ]
Iqbal, Mohammad Shameel [1 ]
Romerio, Fabio [1 ]
机构
[1] Johns Hopkins Univ, Dept Mol & Comparat Pathobiol, Sch Med, Baltimore, MD 21205 USA
关键词
HIV-1; antisense RNA; non-coding RNA; epigenetic regulation; negative-sense promoter; histone deacetylation; histone methylation; latency-reversing agents; shock and kill; HUMAN-IMMUNODEFICIENCY-VIRUS; NEGATIVE ELONGATION-FACTOR; LONG TERMINAL REPEAT; HUMAN-FACTORS YY1; P-TEFB; POLYMERASE-II; EXPRESSION; PROMOTER; TYPE-1; TAT;
D O I
10.3390/ncrna9010005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nucleosomes positioned on the HIV-1 5 ' long terminal repeat (LTR) regulate sense transcription as well as the establishment and maintenance of latency. A negative-sense promoter (NSP) in the 3 ' LTR expresses antisense transcripts with coding and non-coding activities. Previous studies identified cis-acting elements that modulate NSP activity. Here, we used the two chronically infected T cell lines, ACH-2 and J1.1, to investigate epigenetic regulation of NSP activity. We found that histones H3 and H4 are present on the 3 ' LTR in both cell lines. Following treatment with histone deacetylase inhibitors (HDACi), the levels of H3K27Ac increased and histone occupancy declined. HDACi treatment also led to increased levels of RNA polymerase II (RNPII) at NSP, and antisense transcription was induced with similar kinetics and to a similar extent as 5 ' LTR-driven sense transcription. We also detected H3K9me2 and H3K27me3 on NSP, along with the enzymes responsible for these epigenetic marks, namely G9a and EZH2, respectively. Treatment with their respective inhibitors had little or no effect on RNPII occupancy at the two LTRs, but it induced both sense and antisense transcription. Moreover, the increased expression of antisense transcripts in response to treatment with a panel of eleven latency-reversing agents closely paralleled and was often greater than the effect on sense transcripts. Thus, HIV-1 sense and antisense RNA expression are both regulated via acetylation and methylation of lysine 9 and 27 on histone H3. Since HIV-1 antisense transcripts act as non-coding RNAs promoting epigenetic silencing of the 5 ' LTR, our results suggest that the limited efficacy of latency-reversing agents in the context of 'shock and kill' cure strategies may be due to concurrent induction of antisense transcripts thwarting their effect on sense transcription.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA
    Taylor, Jared P.
    Armitage, Lucas H.
    Aldridge, Daniel L.
    Cash, Melanie N.
    Wallet, Mark A.
    BIOLOGY OPEN, 2020, 9 (12):
  • [2] Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells
    Gray, Lachlan R.
    On, Hung
    Roberts, Emma
    Lu, Hao K.
    Moso, Michael A.
    Raison, Jacqueline A.
    Papaioannou, Catherine
    Cheng, Wan-Jung
    Ellett, Anne M.
    Jacobson, Jonathan C.
    Purcell, Damian F. J.
    Wesselingh, Steve L.
    Gorry, Paul R.
    Lewin, Sharon R.
    Churchill, Melissa J.
    JOURNAL OF NEUROVIROLOGY, 2016, 22 (04) : 455 - 463
  • [3] Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells
    Lachlan R. Gray
    Hung On
    Emma Roberts
    Hao K. Lu
    Michael A. Moso
    Jacqueline A. Raison
    Catherine Papaioannou
    Wan-Jung Cheng
    Anne M. Ellett
    Jonathan C. Jacobson
    Damian F. J. Purcell
    Steve L. Wesselingh
    Paul R. Gorry
    Sharon R. Lewin
    Melissa J. Churchill
    Journal of NeuroVirology, 2016, 22 : 455 - 463
  • [4] NSC95397 Is a Novel HIV-1 Latency-Reversing Agent
    Doyle, Randilea Nichols
    Yang, Vivian
    Kayode, Yetunde I.
    Damoiseaux, Robert
    Taylor, Harry E.
    Fregoso, Oliver I.
    VIRUSES-BASEL, 2024, 16 (11):
  • [5] Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents
    Sorensen, Eric S.
    Macedo, Amanda B.
    Resop, Rachel S.
    Howard, J. Natalie
    Nell, Racheal
    Sarabia, Indra
    Newman, Daniel
    Ren, Yanqin
    Jones, R. Brad
    Planelles, Vicente
    Spivak, Adam M.
    Bosque, Alberto
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (08)
  • [6] Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir
    Darcis, Gilles
    Bouchat, Sophie
    Kula, Anna
    Van Driessche, Benoit
    Delacourt, Nadege
    Vanhulle, Caroline
    Avettand-Fenoel, Veronique
    De Wit, Stephane
    Rohr, Olivier
    Rouzioux, Christine
    Van Lint, Carine
    AIDS, 2017, 31 (02) : 181 - 189
  • [7] Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
    Gupta, Vipul
    Dixit, Narendra M.
    PLOS COMPUTATIONAL BIOLOGY, 2018, 14 (02)
  • [8] A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro
    Matsuda, Kouki
    Islam, Saiful
    Takada, Toru
    Tsuchiya, Kiyoto
    Tan, Benjy Jek Yang
    Hattori, Shin-ichiro
    Katsuya, Hiroo
    Kitagawa, Kosaku
    Kim, Kwang Su
    Matsuo, Misaki
    Sugata, Kenji
    Delino, Nicole S.
    Gatanaga, Hiroyuki
    Yoshimura, Kazuhisa
    Matsushita, Shuzo
    Mitsuya, Hiroaki
    Iwami, Shingo
    Satou, Yorifumi
    Maeda, Kenji
    CELL REPORTS METHODS, 2021, 1 (08):
  • [9] Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products
    Richard, Khumoekae
    Williams, David E.
    de Silva, E. Dilip
    Brockman, Mark A.
    Brumme, Zabrina L.
    Andersen, Raymond J.
    Tietjen, Ian
    VIRUSES-BASEL, 2018, 10 (07):
  • [10] Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?
    Salahong, Thanarat
    Schwartz, Christian
    Sungthong, Rungroch
    VIRUSES-BASEL, 2021, 13 (06):